NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Thomas A. Moore, chairman and CEO of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, issued the following statement to shareholders Friday, September 24, 2010:
